pd 153035 has been researched along with Diffuse Parenchymal Lung Disease in 1 studies
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gefitinib is an anticancer drug developed to inhibit the tyrosine kinase activity of the epidermal growth factor receptor (EGFR)." | 1.38 | Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease. ( Matsuo, K; Takada, Y, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takada, Y | 1 |
| Matsuo, K | 1 |
1 other study available for pd 153035 and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Topics: Animals; Antineoplastic Agents; Chemokine CCL2; Disease Models, Animal; ErbB Receptors; Erlotinib Hy | 2012 |